FY2025 Earnings Forecast for DNTH Issued By Lifesci Capital

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Research analysts at Lifesci Capital lifted their FY2025 earnings per share (EPS) estimates for Dianthus Therapeutics in a note issued to investors on Wednesday, March 12th. Lifesci Capital analyst R. Katkhuda now expects that the company will post earnings per share of ($2.50) for the year, up from their prior forecast of ($2.53). The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.61) per share.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The firm had revenue of $1.33 million during the quarter, compared to analysts’ expectations of $1.40 million.

DNTH has been the subject of a number of other research reports. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday. Guggenheim reaffirmed a “buy” rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday. Raymond James upgraded shares of Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. TD Cowen initiated coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They set a “buy” rating for the company. Finally, Wedbush restated an “outperform” rating and issued a $36.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Dianthus Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $52.14.

Dianthus Therapeutics Stock Performance

Shares of DNTH stock opened at $21.33 on Friday. The firm has a market cap of $631.30 million, a price-to-earnings ratio of -8.53 and a beta of 1.82. Dianthus Therapeutics has a 52 week low of $18.13 and a 52 week high of $33.77. The firm’s 50-day simple moving average is $22.61 and its two-hundred day simple moving average is $24.92.

Institutional Trading of Dianthus Therapeutics

A number of large investors have recently made changes to their positions in the stock. R Squared Ltd bought a new position in Dianthus Therapeutics in the fourth quarter worth about $26,000. Quest Partners LLC grew its stake in shares of Dianthus Therapeutics by 112,400.0% during the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock worth $31,000 after acquiring an additional 1,124 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Dianthus Therapeutics during the fourth quarter worth about $33,000. KBC Group NV purchased a new stake in shares of Dianthus Therapeutics during the fourth quarter worth about $35,000. Finally, BNP Paribas Financial Markets purchased a new stake in shares of Dianthus Therapeutics during the fourth quarter worth about $59,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.